Design, synthesis, and biological evaluation of new (2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-ol ethers as inhibitors of human and Trypanosoma cruzi oxidosqualene cyclase

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 1, 2007, Pages 220-224

  Galli, Ubaldina ^a   Oliaro Bosso, Simonetta ^b   Taramino, Silvia ^b   Venegoni, Serena ^a   Pastore, Emanuele ^a   Tron, Gian Cesare ^a   Balliano, Gianni ^b   Viola, Franca ^b   Sorba, Giovanni ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Chagas disease; Lanosterol synthase; Oxidosqualene cyclase; Truncated squalene derivatives; Trypanosoma cruzi

Indexed keywords

ALKYL GROUP; AROMATIC COMPOUND; BENZENE DERIVATIVE; BIPHENYL DERIVATIVE; DIMETHYLAMINE; ENZYME INHIBITOR; ETHER DERIVATIVE; MICROBIAL ENZYME; NAPHTHYL GROUP; OXIDOSQUALENE CYCLASE; OXIDOSQUALENE CYCLASE INHIBITOR; SQUALENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; IC 50; NONHUMAN; PNEUMOCYSTIS CARINII; REACTION ANALYSIS; SACCHAROMYCES CEREVISIAE; STEROL SYNTHESIS; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI;

ANIMALS; ANTIPARASITIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INTRAMOLECULAR TRANSFERASES; PHENYL ETHERS; SQUALENE; TRYPANOSOMA CRUZI;

PNEUMOCYSTIS CARINII; TRYPANOSOMA CRUZI;

EID: 33845789647     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.09.058     Document Type: Article

References (48)

1. Nes W.D. Recent. Adv. Phytochem. 24 (1990) 283
2. Wendt K.U., Schulz G.E., Corey E.J., and Liu D.R. Angew. Chem., Int. Ed. 39 (2000) 2812
3. Huff M.W., and Telford D.E. Trends Pharmacol. Sci. 26 (2005) 335
4. Brown G.D. Nat. Prod. Rep. 15 (1998) 653
5. Abe, I.; Prestwich, G. D. Comprehensive Natural Products Chemistry. Isoprenoids Including Carotenoids and Steroids; Cane, D., Ed.; Elsevier: Oxford, 1999; Vol. 2, pp 267-298.
6. Abe I., Rohmer M., and Prestwich G.D. Chem. Rev. 93 (1993) 2189
7. Abe I., Tomesch J.C., Wattanasin S., and Prestwich G.D. Nat. Prod. Rep. 11 (1994) 279
8. Grosa G., Viola F., Ceruti M., Brusa P., Delprino L., Dosio F., and Cattel L. Eur. J. Med. Chem. 29 (1994) 17
9. Viola F., Brusa P., Balliano G., Ceruti M., Boutaud O., Schuber F., and Cattel L. Biochem. Pharmacol. 50 (1995) 787
10. Cattel L., and Ceruti M. Crit. Rev. Biochem. Mol. Biol. 33 (1998) 353
11. Abe I., Zheng Y.F., and Prestwich G.D. J. Enzyme Inhib. 13 (1998) 385
12. Brown G.R., Hollinshead D.M., Strokes E.S.E., Clarke D.S., Eakin M.A., Foubister A.J., Glossup S.C., Griffiths D., Johnson M.C., McTaggart F., Mirrlees D.J., Smith G.J., and Wood R. J. Med. Chem. 42 (1999) 1306
13. Grunler J., Ericsson J., and Dallner G. Biochim. Biophys. Acta 1212 (1994) 259
14. Adams, J. L.; Metcalf, B. Comprehensive Medicinal Chemistry. Samers, P. G., Taylor, J. B., Eds.; Pergamon: Oxford 1990, Vol. 2, pp 333-364.
15. Buckner F.S., Griffin I.H., Wilson A.J., and Van Voorhis W.C. Antimicrob. Agents Chemother. 45 (2001) 1210
16. Hinshaw J.C., Suh D.Y., Garnier P., Buckner F.S., Eastman R.T., Matsuda S.P.T., Joubert B.M., Coppens I., Joiner K.A., Merali S., Nash T.E., and Prestwich G.D. J. Med. Chem. 46 (2003) 4240
17. Kirchhoff L.V. N. Engl. J. Med. 329 (1993) 639
18. Morel C.M. Parasitol. Today 16 (2000) 522
19. Croft S.L. Parasitology 114 (1997) 3
20. Croft S.L., Barret M.P., and Urbina J.A. Trends Parasitol. 21 (2005) 508
21. Urbina J.A. Curr. Opin. Infect. Dis. 14 (2001) 733
22. Control of Chagas disease, World Health Organization. Tech. Rep. Ser. 2002, 905 i-vi, 1-109.
23. Fournet A., and Muñoz V. Curr. Top. Med. Chem. 2 (2002) 1215
24. Paulino M., Iribarne F., Dubin M., Aguilera-Morales S., Tapia O., and Stoppani A.O.M. Mini-Rev. Med. Chem. 5 (2005) 499
25. Joubert B.M., Buckner F.S., and Matsuda S.P.T. Org. Lett. 3 (2001) 1957
26. Segura M.J.R., Lodeiro S., Meyer M.M., Patel A.J., and Matsuda S.P.T. Org. Lett. 4 (2002) 4459
27. Flaherty P.T., and Georg G.I. ChemTracs 13 (2000) 237
28. Rohdich F., Kis K., Bacher A., and Eisenreich W. Curr. Opin. Chem. Biol. 5 (2001) 535
29. Oliaro-Bosso S., Ceruti M., Balliano G., Milla P., Rocco F., and Viola F. Lipids 40 (2005) 1257
30. For examples of such a strategy, see:. Rahier A., Narula A.S., Benveviste P., and Schmitt P. Biochem. Biophys. Res. Commun. 92 (1980) 20
31. Cattel L., Ceruti M., Viola F., Delprino L., Balliano G., Duriatti A., and Bouvier-Navé P. Lipids 21 (1986) 31
32. Volkert M., Uwai K., Tebbe A., Popkirova B., Wagner M., Kuhlmann J., and Waldmann H. J. Am. Chem. Soc. 125 (2003) 12749
33. Corey E.J., and Shieh W.C. Tetrahedron Lett. 33 (1992) 6435
34. Umbreit M.A., and Sharpless K.B. J. Am. Chem. Soc. 99 (1977) 5526
35. Sharpless K.B., and Lauer R.F. J. Am. Chem. Soc. 94 (1972) 7154
36. Stephenson L.M., and Speth D.R. J. Org. Chem. 44 (1979) 4683
37. Fairlamb I.J.S., Dickinson J.M., and Pegg M. Tetrahedron Lett. 42 (2001) 2205
38. Needles H.L., and Whitfield R.E. J. Org. Chem. 31 (1966) 989
39. Woodbury R.P., and Rathke M.W. J. Org. Chem. 42 (1977) 1688
40. Woodbury R.P., and Rathke M.W. J. Org. Chem. 43 (1978) 881
41. 3): δ 138.5, 134.9, 124.4, 124.3, 59.3, 59.1, 45.3, 39.5, 37.2, 26.2, 25.5, 16.3, 16.2.
42. 4) at a flow rate of 0.7 ml/min and a sample injection volume of 20 μl, λ = 220 nm. For all compounds, eluants A and B were delivered isocratically at a 20:80 ratio. All four compounds displayed a purity of at least 95%.
43. The S. cerevisiae strains: SMY8[pBJ1.21], expressing the OSC of T. cruzi; SMY8[pSM61.21], expressing the wild-type yeast OSC; SMY8[pBJ4.21], expressing the P. carinii OSC were kindly provided by Professor S. P. T. Matsuda [Department of Chemistry and Biochemistry and Cell Biology, Rice University, Houston, TX, USA. For references and cultural conditions see Refs. 11, 13, and 24. The enzymatic activity was determined as described in Refs. 13 and 24.
44. Ruf A., Muller F., D'Arcy B., Stihle M., Kusznir E., Handschin C., Morand O.H., and Thoma R. Biochem. Biophys. Res. Commun. 315 (2004) 247
45. Pichia pastoris cells expressing human OSC were kindly provided by Ralf Thoma from Hoffmann-La Roche Ltd, Pharma Research Discovery (CH-4070 Basel, Switzerland). Cultural conditions were as in Ref. 22 and cell-free homogenates were prepared as described for S. cerevisiae cells in Ref. 13. Enzymatic assays were determined in phosphate buffer, pH 8, at 45 °C as described in Ref. 13.
46. Oliaro-Bosso S., Viola F., Matsuda S.T.P., Cravotto G., Tagliapietra S., and Balliano G. Lipids 39 (2004) 1007
47. Thoma R., Schulz-Gasch T., D'Arcy B., Benz J., Aebi J., Dehmlow H., Hennig M., Stihle M., and Ruf A. Nature 432 (2004) 118
48. 4 cells were suspended and grown for 24 h in 950 μl DMEM containing 10% (v/v) lipid-depleted serum. After a 3 h preincubation in the presence of inhibitor, labeled acetate (1 μCi/well) was added. After further 3 h incubation, the medium was removed and the cells were lysed with 500 μl of 0.1 N NaOH for 30 min. After saponification with 1.5 ml of 10% (w/v) methanolic KOH for 1 h at 80 °C, nonsaponifiable lipids were extracted with petroleum ether and separated on TLC plates (Alufolien Kieselgel 60F254, Merck, Darmstadt, Germany) using n-hexane/ethyl acetate (85:15 v/v) as a developing solvent and authentic standards of cholesterol, lanosterol, dioxidosqualene, oxidosqualene, and squalene as reference compounds. Radioactivity in separated bands was measured using a System 200 Imaging Scanner (Hewlett-Packard, Palo Alto, CA, USA).